TKNO — Alpha Teknova, Inc.

Summary of TKNO Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $11 million, up 13% year-over-year; first Q1 over $11 million in three years.
• Lab Essentials Revenue: $8.4 million, a 3% increase from $8.1 million in Q1 2025.
• Clinical Solutions Revenue: $2.1 million, an 85% increase from $1.2 million in Q1 2025.
• Gross Profit: $3.8 million, up from $3.0 million; gross margin improved to 34.2% from 30.7%.
• Operating Expenses: $8.1 million, slightly up from $8.0 million due to increased sales and marketing spending.
• Net Loss: $4.6 million, or negative $0.08 per diluted share, consistent with the prior year.
• Adjusted EBITDA: Negative $2.0 million, improved from negative $2.5 million.
• Free Cash Outflow: $3.6 million, down from $4.3 million year-over-year.
• Cash Position: $17.8 million in cash and equivalents as of March 31, 2026.

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong performance in Clinical Solutions attributed to an increase in customer orders and average revenue per customer.
• Market Conditions: Stabilization observed in end markets, with increased customer engagement and order sizes.
• Operational Improvements: Increased production capacity through automation and digitization of batch records.
• Sales and Marketing Investment: $2 million annual increase to enhance lead generation and sales capabilities, expected to impact revenue positively by early 2027.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated total revenue guidance of $42 million to $44 million, implying about 6% growth.
• Long-term Growth Expectations: Anticipated approximately 20% revenue growth in 2027, driven by improved market conditions and customer advancements in clinical phases.
• Gross Margin Outlook: Expected to remain in the mid-30s percentage range for 2026.

4. Challenges and Points of Concern

• Customer Base Changes: Noted a decrease in the number of Lab Essentials customers, though revenue per customer increased.
• Market Uncertainty: Ongoing macroeconomic uncertainties and the need for more durable order patterns before adjusting guidance.
• Lumpiness in Revenue: Clinical Solutions revenue can be volatile due to larger order sizes, leading to potential quarter-to-quarter variability.

5. Notable Q&A Insights

• Customer Segmentation: Some bifurcation observed between earlier-stage and later-stage biotech customers, with encouraging engagement from smaller biotechs.
• Clinical Development Pipeline: Approximately 70 therapies supported, with five nearing completion in phase two or three.
• AI Impact: Early signs of increased spending in wet lab activities due to AI initiatives, although not yet material.
• Sales Associate Ramp-up: Typically takes six to twelve months to see significant impacts from newly onboarded sales associates.

Overall, TKNO reported a solid start to 2026, with notable growth in Clinical Solutions and a positive outlook for future revenue growth, albeit tempered by macroeconomic uncertainties and the need for sustained customer engagement.